Key Takeaways
- Zymeworks has finalized an all-cash acquisition of Theravance Biopharma valued at $929 million, offering $17 per share
- The acquisition price represents a 3.6% discount compared to Theravance’s previous closing price of $17.63
- Yupelri, Theravance’s sole commercialized medication for COPD, recorded $266.6 million in U.S. net revenue during 2025
- Premarket activity showed Theravance shares declining 2.8% while Zymeworks retreated 1.4%
- Transaction completion is anticipated in the latter half of 2026, with expectations of positive impacts on Zymeworks’ earnings and cash generation
In an all-cash transaction valued at $929 million, Zymeworks has announced plans to acquire Theravance Biopharma, offering shareholders $17 per share—representing a 3.6% markdown from Theravance’s Friday closing value of $17.63.
Investor sentiment proved lukewarm. During Monday’s premarket session, Theravance shares retreated 2.8% to $17.14. Zymeworks experienced a 1.4% decline.
The below-market acquisition price stands out as atypical in the biotech M&A landscape and helps explain the negative market reaction. Most acquisition agreements include a premium above current trading levels.
That said, the offer does provide a 22% gain over Theravance’s March 3 trading level—the day the company disclosed disappointing late-stage clinical results for ampreloxetine, an investigational treatment for a rare medical condition.
Following the clinical setback, Theravance initiated a corporate restructuring that eliminated approximately 50% of its employee base. Subsequently, the company launched a formal strategic review process to evaluate potential transactions, including an outright sale.
Monday’s announcement marks the conclusion of that strategic exploration.
The Acquisition’s Core Assets
The centerpiece of this transaction is Yupelri, an FDA-approved nebulized COPD therapy administered once daily. This represents Theravance’s sole revenue-generating product.
Yupelri produced $266.6 million in U.S. net revenue throughout 2025, reflecting 12% growth versus 2024. During the initial quarter of 2026, U.S. net revenue reached $62.4 million, marking a 7% year-over-year increase.
Under a partnership agreement with Viatris, Theravance receives a 35% net profit share on U.S. Yupelri sales. According to Zymeworks, these royalty payments and profit participation currently deliver approximately $60 million in annual cash generation.
This transaction represents a strategic pivot for Zymeworks—historically concentrated on oncology therapeutics—into the competitive respiratory disease sector, where it will compete against pharmaceutical giants including GSK, AstraZeneca, and Boehringer Ingelheim.
Ampreloxetine’s Future Disposition
The discontinued clinical program won’t be entirely abandoned. Under the transaction terms, Theravance shareholders will obtain contingent value rights providing them with 80% of any future revenue generated from licensing, selling, or otherwise commercializing ampreloxetine within the next decade.
Zymeworks will retain the remaining 20% stake and has indicated interest in exploring monetization opportunities for this asset.
Zymeworks projects the acquisition will enhance both earnings performance and cash flow generation following closure, currently scheduled for the second half of 2026.
Completion of the transaction requires both regulatory clearance and approval from Theravance’s shareholder base.
Yupelri’s Q1 2026 U.S. net revenue of $62.4 million marked a 7% increase compared to the corresponding period in the prior year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
